Sanofi’s PD-1 inhibitor starts EU review for skin cancer

Sanofi’s PD-1 inhibitor starts EU review for skin cancer: pCemiplimab could be the first PD-1-targeting drug approved for CSCC/p

Commentaires

Articles les plus consultés